Carboxylate ligand modified ferric iron hydroxide compositions for use in the treatment or prevention of iron deficiency associated with liver diseases
AssigneeNemysis Limited
InventorsDanilo Casadei Massari, Maria Cristina Comelli, Jonathan Powell, Nuno Faria, Katharina Kessler
Life of this patent
Estimating the term…
Abstract
The use of carboxylate ligand modified ferric iron hydroxide compositions for the treatment or prevention of iron deficiency associated with liver diseases is disclosed, and more particularly to the class of Iron Hydroxide Adipate Tartrate (IHAT) materials for 10 use in the treatment or prevention of iron deficiency associated with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).
Claims23
A method for the treatment or prevention of iron deficiency associated with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) in a subject in need thereof, comprising administering a carboxylate ligand modified ferric iron oxo-hydroxide composition to the subject,
- wherein the carboxylate ligand modified ferric iron oxo-hydroxide has a three dimensional polymeric structure in which the carboxylate ligands are non-stoichiometrically substituted for the oxo or hydroxy groups of the ferric iron oxo-hydroxide so that some of the ligand integrates into the solid phase by formal metal-ligand bonding, and/or
- wherein the three dimensional polymeric structure of the carboxylate ligand modified ferric iron oxo-hydroxide is such that the substitution of the oxo or hydroxy groups by the carboxylate ligands is substantially random.
A method for the treatment or prevention of iron deficiency associated with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) in a subject, comprising administering an effective amount of Iron Oxo-hydroxide Adipate Tartrate (IHAT) to the subject.
Dependencies are inferred from the claim text.